000			04030nam a22004097a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a0732-183X
040			_aOvid MEDLINE(R)
099			_a38828938
245			_aECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
251			_aJournal of Clinical Oncology. :JCO2400526, 2024 Jun 03
252			_aJ Clin Oncol. :JCO2400526, 2024 Jun 03
253			_aJournal of clinical oncology : official journal of the American Society of Clinical Oncology
260			_c2024
260			_fFY2024
260			_p2024 Jun 03
265			_saheadofprint
265			_tPublisher
266			_d2024-08-07
266			_z2024/06/03 08:03
501			_aAvailable online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008
520			_aCONCLUSION: Germline variation did not predict risk of TIPN in Black women receiving (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel. Once weekly paclitaxel was associated with significantly more grade 2-4 TIPN and required more dose reductions than once every 3 weeks docetaxel.
520			_aMETHODS: Women with early-stage breast cancer who self-identified as Black and had intended to receive (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel were eligible, with planned accrual to 120 patients in each arm. Genotyping was performed to determine germline neuropathy risk. Grade 2-4 TIPN by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 was compared between high- versus low-risk genotypes and between once weekly paclitaxel versus once every 3 weeks docetaxel within 1 year. Patient-rated TIPN and patient-reported outcomes were compared using patient-reported outcome (PRO)-CTCAE and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity.
520			_aPURPOSE: Black women experience higher rates of taxane-induced peripheral neuropathy (TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for early-stage breast cancer, leading to more dose reductions and higher recurrence rates. EAZ171 aimed to prospectively validate germline predictors of TIPN and compare rates of TIPN and dose reductions in Black women receiving (neo)adjuvant once weekly paclitaxel and once every 3 weeks docetaxel for early-stage breast cancer.
520			_aRESULTS: Two hundred and forty of 249 enrolled patients had genotype data, and 91 of 117 (77.8%) receiving once weekly paclitaxel and 87 of 118 (73.7%) receiving once every 3 weeks docetaxel were classified as high-risk. Physician-reported grade 2-4 TIPN was not significantly different in high- versus low-risk genotype groups with once weekly paclitaxel (47% v 35%; P = .27) or with once every 3 weeks docetaxel (28% v 19%; P = .47). Grade 2-4 TIPN was significantly higher in the once weekly paclitaxel versus once every 3 weeks docetaxel arm by both physician-rated CTCAE (45% v 29%; P = .02) and PRO-CTCAE (40% v 24%; P = .03). Patients receiving once weekly paclitaxel required more dose reductions because of TIPN (28% v 9%; P < .001) or any cause (39% v 25%; P = .02).
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aHematology/Oncology
657			_aJournal Article
700			_aChitalia, Ami _bMWHC
790			_aSchneider BP, Zhao F, Ballinger TJ, Garcia SF, Shen F, Virani S, Cella D, Bales C, Jiang G, Hayes L, Miller N, Srinivasiah J, Stringer-Reasor EM, Chitalia A, Davis AA, Makower DF, Incorvati J, Simon MA, Mitchell EP, DeMichele A, Miller KD, Sparano JA, Wagner LI, Wolff AC
856			_uhttps://dx.doi.org/10.1200/JCO.24.00526 _zhttps://dx.doi.org/10.1200/JCO.24.00526
858			_yChitalia, Ami _uhttps://orcid.org/0009-0001-0274-2150 _zhttps://orcid.org/0009-0001-0274-2150
942			_cART _dArticle
999			_c14405 _d14405